A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects
Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This will be an open label, prospective, multi-center, comparative, interventional study to
evaluate safety and efficacy of Artemisinin 500 mg in subjects with mild to moderate
COVID-19. Initially subjects having mild to moderate COVID-19 will be screened as per
predefined eligibility criteria for the study. Eligible 120 subjects will be enrolled to
receive treatment with Artemisinin and SOC (Standard of Care as per CLINICAL MANAGEMENT
PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate
General of Health Services (EMR Division)) or SOC. Subjects will be randomized in 2:1 ratio.
Group 1 will have 80 subjects and Group 2 will have 40 subjects.